Abstract
The intrinsic blood coagulation pathways depend heavily on factor VIII, a glycoprotein cofactor. Hemophilia A, an X-linked dominant disease, is treated with FVIII, a very complex therapeutic protein commercially available. It is currently one of the most extensive and significant coagulation factors. Two isolated plasma and recombinant lyophilized FVIII concentrates are used to treat hemorrhagic illness in hemophilia A sufferers. Plasma-extracted products separated from humanoid blood can be substituted with recombinant FVIII (rFVIII) products, which are free of both humanoid and carnal proteins and transcribed in eukaryotic cells. In regard to fluid flow, mixing, heat, and mass transfer phenomena, the upstream and downstream manufacturing processes of rFVIII will be briefly reviewed in this publication.
Funder
No supporting institution
Publisher
Duzce Universitesi Bilim ve Teknoloji Dergisi
Reference28 articles.
1. [1] A process of purifying coagulation factor VIII, by C. Borgvall, U. Ericsson, G. Gilljam, M. Jernberg, and S. Winge. (2009, Dec. 30). International Patent WO2009/156430 [Online]. Available: https://patentimages.storage.googleapis.com/4e/80/26/2021dea5d707ba/WO2009156430A1.pdf
2. [2] A. Coppola, M. Di Capua, M. N. Di Minno, M. Di Palo, E. Marrone, P. Ierano, C. Arturo, A. Tufano, and A. M. Cerbone, “Treatment of hemophilia: a review of current advances and ongoing issues,” Journal of Blood Medicine, vol. 1, pp. 183–195, Aug. 2010
3. [3] M. De Jesus and F. M. Wurm, “Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors,” European Journal of Pharmaceuticals and Biopharmaceutics, vol. 78, no. 2, pp. 184–188, 2011
4. [4] S. Delignat, I. Peyron, M. El Ghazaly, S. V. Kaveri, J. Rohde, F. Mueller, and S. Lacroix-Desmazes, “Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors,” Cellular Immunology, vol. 331, pp. 22–29, Sep. 2018
5. [5] M. Franchini, “The modern treatment of haemophilia: a narrative review,” Blood Transfusion, vol. 11, no. 2, pp. 178–182, Apr. 2013